Macrolide Therapeutics in COVID-19 Management

Macrolide antibiotics, notably azithromycin and clarithromycin, were rapidly repurposed at the outset of the COVID-19 pandemic owing to their recognised anti-inflammatory, immunomodulatory and potential antiviral properties. Beyond bacterial inhibition, macrolides have been shown in vitro to interfere with endosomal acidification, attenuate excessive cytokine release and enhance antiviral interferon responses. Clinically, these properties offered a promising adjunct to antiviral and supportive therapies, particularly in settings of hyperinflammation or secondary bacterial infection. Nevertheless, large-scale trials have largely failed to demonstrate a consistent benefit in reducing mortality, hospital stay or progression to severe disease. The widespread empirical use of macrolides has further raised concerns regarding antimicrobial stewardship and the emergence of resistance. Recent research has therefore shifted towards refining patient selection, optimising dosing regimens and elucidating precise immunological mechanisms. Continued exploration of novel macrolide derivatives and combination strategies seeks to harness their host-directed effects while minimising microbial resistance. Ultimately, the global significance of macrolide therapeutics in COVID-19 management lies in balancing modest immunomodulatory gains against the imperatives of antibiotic conservation and evidence-based practice.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Macrolide Therapeutics in COVID-19 Management publication trend

The graph below shows the total number of articles in macrolide therapeutics in covid-19 management across all publications each year (not limited to Nature Index journals).

Technical terms

Macrolide: A class of antibiotics defined by a large lactone ring that exerts antibacterial, antiviral and immunomodulatory actions.

Immunomodulation: The process of regulating or normalising immune system activity through modification of cytokine profiles and immune cell function.

Cytokine storm: An excessive release of pro-inflammatory cytokines that can lead to tissue damage and multi-organ dysfunction in severe viral infections.

Randomised controlled trial: A study design in which participants are allocated by chance to receive an intervention or control, minimising bias in outcome assessment.

Antimicrobial stewardship: The coordinated efforts to optimise antibiotic use to combat resistance, improve patient outcomes and preserve drug efficacy.

References

1. The Immunomodulatory Effects of Macrolides—A Systematic Review of the Underlying Mechanisms. Frontiers in Immunology (2018).
2. Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. The Lancet (2021).
3. Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial. The Lancet (2021).
4. Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial. The Lancet Respiratory Medicine (2021).
5. Prevalence of azithromycin resistance after the COVID-19 era in clinical bacterial isolates from a tertiary care hospital in Gurugram, India. Frontiers in Microbiology (2025).